Which test can predict the return of renal function in a patient with the tumor lysis syndrome?
**Core Concept**
Tumor lysis syndrome (TLS) is a life-threatening complication that occurs when large numbers of cancer cells die rapidly, releasing intracellular contents into the bloodstream. This can lead to hyperkalemia, hyperphosphatemia, hypocalcemia, and acute kidney injury (AKI). The ability to predict the return of renal function is crucial in managing patients with TLS.
**Why the Correct Answer is Right**
The correct answer is the test that assesses the glomerular filtration rate (GFR), which is a measure of kidney function. In patients with TLS, the GFR can decrease significantly due to the release of uric acid crystals and other toxic substances that damage the renal tubules. The **serum creatinine level** is a commonly used marker to estimate GFR. As renal function improves, the serum creatinine level decreases, indicating a potential return of renal function.
**Why Each Wrong Option is Incorrect**
* **Option A:** Serum lactate dehydrogenase (LDH) levels may be elevated in TLS due to the breakdown of cancer cells, but they do not directly predict renal function recovery.
* **Option B:** White blood cell count (WBC) may be elevated in TLS due to the release of cytokines, but it is not a reliable indicator of renal function recovery.
* **Option C:** C-reactive protein (CRP) levels may be elevated in TLS due to the inflammatory response, but they do not directly predict renal function recovery.
**Clinical Pearl / High-Yield Fact**
In patients with TLS, the **serum creatinine level** is a critical marker to monitor, as it can help guide the management of renal replacement therapy and other supportive care measures.
**Correct Answer:** C. Serum creatinine level.